companydata.dkcompanydata.dk

PHARMA EVIDENCE ApS: Financial statements 2023

CVR: 34586519

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

PHARMA EVIDENCE ApS (CVR 34586519) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -428,457 and a net result of DKK -796,106 compared with DKK 197,361 the year before. Equity in the 2023 report amounted to DKK 252,004. The solvency ratio was 32.2%. The company had 1 employee in the financial year.

Gross Profit
DKK -428,457
Profit/Loss
DKK -796,106
Equity
DKK 252,004
Total Assets
DKK 783,509
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023--428 t.-796 t.252 t.1
2022-552 t.197 t.1 mio.1
2021-196 t.-442 t.851 t.1
2020-1.1 mio.643 t.1.3 mio.1
2019-749 t.221 t.650 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

PHARMA EVIDENCE ApS: The 2022 annual report is outMar 27, 2023

PHARMA EVIDENCE ApS has published its annual report for 2022. Gross profit came to DKK 551,989, and the net result was DKK 197,361.

About PHARMA EVIDENCE ApS

PHARMA EVIDENCE ApS is a Danish company of the type Anpartsselskab based in Farum, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Tove Holm-Larsen. The company is owned by HB World Holding ApS. The company has 1 employee (2023). In 2025, the company reported a gross profit of DKK 64,007 and a net result of DKK 62,147 compared with DKK -179,749 the year before. Equity in the 2025 report amounted to DKK 134,401.

Source: annual report 2025, Danish Business Authority